FDA extends Ryplazim BLA review period for Liminal Biosciences
Category: #healthcare  By Akshay Kedari  Date: 2020-11-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA extends Ryplazim BLA review period for Liminal Biosciences

Clinical stage biopharmaceutical major, Liminal Biosciences Inc., has reportedly announced the extension of its Ryplazim BLA (Biologics License Application) by the U.S. Food and Drug Administration for the treatment of clinical symptoms and signs associated with congenital plasminogen deficiency. Additionally, the target action date for the new PDUFA (Prescription Drug User Fee Act) has also witnessed an extension of three months to June 5, 2021.

The company has lately submitted a response to an FDA information request concerned with the resubmission of the BLA, cite sources. Further, the FDA has also notified Liminal Biosciences on the 6th November 2020. According to the regulator, the submission of additional information forms part of a major amendment, as it consists of considerable new facility or manufacturing information that was not reviewed by or submitted to the FDA at an earlier stage. This, therefore, entitles the regulator in announcing a three month extension for the review process.

As stated by Liminal Biosciences’ CEO, Kenneth Galbraith, the company is disappointed by the extension of the review period by the Food and Drug Administration and looks ahead to continuing discussions with the regulator regarding the review process. Liminal remains dedicated to bringing this much needed treatment to help patients who are diagnosed with this serious disease, added Galbraith.

Liminal BioSciences is a clinical-stage biopharmaceutical company focusing on the development, discovery, and commercialization of new treatments for patients diagnosed with diseases of high unmet medical requirements that are primarily associated with fibrosis, comprising kidney, respiratory, and liver diseases.

The resubmission of the Ryplazim Biologics License Application was originally accepted by the Food and Drug Administration in September 2020 as a Class 2 response to the previously complete response letter given by the food and drug regulator in 2018. The BLA resubmission was reportedly backed by data from a Phase 2/3 clinical trial, that evaluated 15 patients including both adults and pediatric, with C-PLGD more than 48 weeks of therapy with Ryplazim.

 

Source Credits:

https://liminalbiosciences.com/resources/press-releases-2020/liminal-biosciences-announces-fda-extension-of-review-period-for-ryplazim-plasminogen-bla

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Tencent Cloud boosts its footprint with launch of Indonesia data center
Tencent Cloud boosts its footprint with launch of Indonesia data center
By Akshay Kedari

Tencent Cloud has announced the launch of an Internet Data Center (IDC) in Indonesia, to provide cus...

U.S. FDA extends review period of Pfizer’s abrocitinib by three months
U.S. FDA extends review period of Pfizer’s abrocitinib by three months
By Akshay Kedari

The clinical tests of Pfizer’s drug included adolescents as well as adults with moderate-to-...

TIM Brazil picks Ceragon Networks to partake in TIP 5G OpenRAN trials
TIM Brazil picks Ceragon Networks to partake in TIP 5G OpenRAN trials
By Akshay Kedari

Ceragon Networks Ltd., an Israel-based networking equipment vendor, has reportedly been chosen by th...